These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17125248)

  • 1. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
    Trotter BW; Nanda KK; Kett NR; Regan CP; Lynch JJ; Stump GL; Kiss L; Wang J; Spencer RH; Kane SA; White RB; Zhang R; Anderson KD; Liverton NJ; McIntyre CJ; Beshore DC; Hartman GD; Dinsmore CJ
    J Med Chem; 2006 Nov; 49(24):6954-7. PubMed ID: 17125248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.
    Blass BE; Fensome A; Trybulski E; Magolda R; Gardell SJ; Liu K; Samuel M; Feingold I; Huselton C; Jackson CM; Djandjighian L; Ho D; Hennan J; Janusz JM
    J Med Chem; 2009 Nov; 52(21):6531-4. PubMed ID: 19888755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
    Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
    Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.
    Plouvier B; Beatch GN; Jung GL; Zolotoy A; Sheng T; Clohs L; Barrett TD; Fedida D; Wang WQ; Zhu JJ; Liu Y; Abraham S; Lynn L; Dong Y; Wall RA; Walker MJ
    J Med Chem; 2007 Jun; 50(12):2818-41. PubMed ID: 17506538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
    Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
    Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
    Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation.
    McBride BF
    J Clin Pharmacol; 2009 Mar; 49(3):258-67. PubMed ID: 19246727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
    Regan CP; Wallace AA; Cresswell HK; Atkins CL; Lynch JJ
    J Pharmacol Exp Ther; 2006 Feb; 316(2):727-32. PubMed ID: 16243963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
    Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.
    Ehrlich JR; Ocholla H; Ziemek D; Rütten H; Hohnloser SH; Gögelein H
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):380-7. PubMed ID: 18427281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
    Guo X; Ma X; Yang Q; Xu J; Huang L; Jia J; Shan J; Liu L; Chen W; Chu H; Wei J; Zhang X; Sun H; Tang Y; You Q
    Eur J Med Chem; 2014 Jun; 81():89-94. PubMed ID: 24824064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
    Lloyd J; Finlay HJ; Atwal K; Kover A; Prol J; Yan L; Bhandaru R; Vaccaro W; Huynh T; Huang CS; Conder M; Jenkins-West T; Sun H; Li D; Levesque P
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5469-73. PubMed ID: 19665893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synthesis and biological activity of 1-(4-alkyloxy)benzyl-1,2,3,4-tetrahydroisoquinolines and related compounds].
    He L; Huang W; Gao H; Peng S
    Yao Xue Xue Bao; 1998 Oct; 33(10):741-7. PubMed ID: 12016926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.
    Piatnitski Chekler EL; Butera JA; Di L; Swillo RE; Morgan GA; Rossman EI; Huselton C; Larsen BD; Hennan JK
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4551-4. PubMed ID: 19616941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
    Guo X; Chen W; Sun H; You Q
    Curr Top Med Chem; 2016; 16(16):1843-54. PubMed ID: 26975505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synthesis and biological activity of substituted benzyl/naphthylmethylisoquinolines and related quaternary ammonium derivatives].
    Xu GY; Peng SX; Hua WY
    Yao Xue Xue Bao; 1994; 29(2):95-106. PubMed ID: 8042518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.
    Peukert S; Brendel J; Pirard B; Strübing C; Kleemann HW; Böhme T; Hemmerle H
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2823-7. PubMed ID: 15125940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
    Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; Didomenico S; Koenig JR; Turner S; Jinkerson T; Drizin I; Hannick SM; Macri BS; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter J; Stewart KD; Oie T; Jarvis MF; Surowy CS; Faltynek CR; Lee CH
    J Med Chem; 2005 Feb; 48(3):744-52. PubMed ID: 15689158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
    Ford JW; Milnes JT
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
    Kajanus J; Antonsson T; Carlsson L; Jurva U; Pettersen A; Sundell J; Inghardt T
    Bioorg Med Chem Lett; 2019 May; 29(10):1241-1245. PubMed ID: 30879840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.